GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MBX Biosciences Inc (NAS:MBX) » Definitions » Buildings And Improvements

MBX (MBX Biosciences) Buildings And Improvements : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is MBX Biosciences Buildings And Improvements?


MBX Biosciences Buildings And Improvements Historical Data

The historical data trend for MBX Biosciences's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MBX Biosciences Buildings And Improvements Chart

MBX Biosciences Annual Data
Trend Dec22 Dec23 Dec24
Buildings And Improvements
- - -

MBX Biosciences Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Buildings And Improvements Get a 7-Day Free Trial - - - - -

MBX Biosciences Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.


MBX Biosciences Business Description

Traded in Other Exchanges
N/A
Address
11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.